A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Israeli Company Deploys New COVID-19 Solution for Coronavirus Wards to Protect Medical Teams

Tamar NIV LTD is a Developer of Neurosurgical Robotic Technology Solutions

Tamar NIV LTD, a developer of neurosurgical robotic technology solutions, today announced that it has developed and deployed a novel protective patient hood that prevents the spread of COVID-19 and protects medical teams when applying non-invasive ventilation therapy for COVID-19 patients.

The product, NIV Greenhouse™ is simple to install and operate personal patient hood connected to a standard cleanroom filter. The NIV Greenhouse™ enables the use of non-invasive ventilation such as CPAP and BiPAP devices in COVID-19 treatment which was previously deemed too risky for medical staff due to the potential for the spread of contagious disease from the patient’s breath.

The safety and protection of attending medical staff is a critical factor in the fight against the virus. The use of the product conforms with the Israel Ministry of Health’s regulation that respiratory support of COVID-19 patients should be provided in a protected environment in order to ensure the safety of the medical staff. The NIV Greenhouse™ combines air filtration around the patient’s head at levels that until now were only available in cleanrooms used in the high-tech industry, together with a personal patient hood that shields the medical staff from the patient’s breath.

“The rapid spread of the COVID-19 virus has necessitated that we dedicate entire wards to these patients in order to prevent the spread of this highly contagious disease, and the swift deployment of Tamar’s NIV Greenhouse™ hood represents a promising tool in protecting our medical teams and our patients,” said Dr. Ori Segol, head of Carmel Medical Center’s Coronavirus ward.

The NIV Greenhouse™ is already contributing to the treatment of COVID-19 patients on the front lines. Initial units have been installed and are in use at both Carmel Medical Center, part of Clalit’s Medical Services, in Haifa, Israel and Ein Kerem Hospital in Hadassah Medical Center in Jerusalem. Multiple personal patient hoods have been connected to a single filtration system thereby further increasing the solution’s efficiency. According to the hospitals, the NIV Greenhouse™ is proving to be a user-friendly, safe and effective tool in their arsenal of solutions. Additional hospitals in Israel and countries around the world have expressed interest in incorporating the product within their COVID-19 wards.

“Our system, which is the first of its kind, enables non-invasive ventilation treatment to COVID-19 patients in a safe manner to both the patient and medical staff,” said Hadas Ziso, Co-founder and CTO of Tamar NIV. “The unique design of our NIV Greenhouse™ hood allows patients to see and speak to the medical team while simultaneously enhancing breathing performance.”

“Our mission at Tamar is to provide medical teams with the best technological advances, enabling treatment with maximum protection,” said Noam Hassidov, CEO of Tamar NIV. “The deployment of our NIV Greenhouse™ hood is the first immediate project from Tamar, with next generations coming to support the new and urgent challenges facing first responders around the world. We want to thank our investors and, in turn, express our gratitude to the medical teams around the world for their tireless work and dedication.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy